Back to top
more

ONCOTHYREON (ONTY)

(Delayed Data from NSDQ)

$1.21 USD

1.21
715,197

+0.02 (1.68%)

Updated Jun 8, 2016 03:59 PM ET

After-Market: $1.22 (%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

0 items in cart

[ONTY]

Reports for Purchase

Showing records 1 - 20 ( 120 total )

Industry: Medical - Biomedical and Genetics

Record: 1

04/22/2016

Industry Report

Pages: 5

AACR Clinical and Preclinical Highlights from the Big Easy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 2

03/16/2016

Company Report

Pages: 7

Elegant Phase 2 Trial Design Provides Multiple Shots on Goal for ONT-380; Reiterate Buy

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 3

12/09/2015

Daily Note

Pages: 3

?380 Shows Potent Activity in CNS and Non-CNS Lesions, Leaving Multiple Registrational Pathways Open

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 4

11/06/2015

Company Report

Pages: 9

3Q15 Update: SABCS Readout Could Recapture ASCO Momentum

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 5

08/07/2015

Company Report

Pages: 12

2Q15 Update-Plans for a Randomized Trial Following Impressive ASCO Showing; Raising PT

Provider: H.C. Wainwright & Co., Inc.

Analyst: BREIDENBACH M

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 6

05/28/2015

Industry Report

Pages: 85

2015 ASCO Planner-Clinical Data to Keep -Da Bears- AwayThis report contains brief updates on the following: ADXS, AGEN, ARIA, CLSN, CTIC, HTBX, ONTY, SGEN, SPPI, STML, TGTX, THLD. These companies are covered in more detail in separate Daily Notes and/or Company Reports.

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 150.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 7

05/12/2015

Company Report

Pages: 11

1Q15 Update-?380 Updates Coming at ASCO

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 8

03/11/2015

Company Report

Pages: 13

4Q14 Update-ONT-380 to Drive Value in 2015; Protocell Applications Spelled Out

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 50.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 9

02/26/2015

Daily Note

Pages: 3

Highlights from Meeting with Management-Growing Menu of Assets to Garner Value

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 10

12/15/2014

Company Report

Pages: 11

The Hunt Begins - ONT-380 Pounces on HER2+ Cancer

Provider: H.C. WAINWRIGHT & CO., INC.

Analyst: BENJAMIN R

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 11

12/15/2014

Company Report

Pages: 4

Dropping Coverage Due to Realignment of Analyst Resources

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 12

11/24/2014

Daily Note

Pages: 5

LIFE SCIENCES AND HEALTH CARE

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 13

11/07/2014

Company Report

Pages: 12

3Q14 Update -All Eyes on San Antonio Breast Cancer Symposium

Provider: H.C. WAINWRIGHT & CO., INC.

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 14

11/07/2014

Company Report

Pages: 6

Q3:14 Earnings, ONT-380 Data to Be Presented at San Antonio Breast Symposium in December, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 15

10/12/2014

Daily Note

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 13

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 16

09/29/2014

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of Sept 29

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 17

08/19/2014

Company Report

Pages: 7

Tecemotide Fails Japanese NSCLC Study, Updating Model for Protocell Opportunity in Rare Diseases, Maintain OUTPERFORM and Lowering PT to $3

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 18

08/14/2014

Company Report

Pages: 6

Q2:14 Earnings; Acquires Alpine Biosciences in All-Stock Deal; Management Speaks at the Wedbush LSMAC; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 25.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 19

05/29/2014

Daily Note

Pages: 4

Transitioning Coverage, ONT-10 and Varlilumab Combo to Enter Clinic, Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: NIERENGARTEN D

Price: 10.00

Research Provided by a Third Party

Industry: Medical - Biomedical and Genetics

Record: 20

05/01/2014

Company Report

Pages: 6

Q1:14 Update, ONT-10 Data Expected at ASCO, and ONT-380 Data Expected by Year End

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party
// eof